-
公开(公告)号：US09604965B2
公开(公告)日：2017-03-28
申请号：US14594274
申请日：2015-01-12
Applicant: Cytokinetics, Inc.
Inventor： Luke W. Ashcraft , Gustave Bergnes , Scott Collibee , Chihyuan Chuang , Jeff Gardina , Bradley P. Morgan , Alex R. Muci , Xiangping Qian , Jeffrey Warrington , Zhe Yang , Pu-Ping Lu , Antonio Romero
IPC: A61K31/50 , C07D237/20 , C07D401/12 , C07D237/24 , C07D401/04 , C07D403/04 , C07D403/06 , C07D409/14 , C07D411/04 , C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D487/10 , C07D513/04 , C07D401/14 , C07D405/14
CPC classification number: A61K31/50 , A61K31/16 , A61K31/166 , C07D207/26 , C07D211/76 , C07D213/16 , C07D231/56 , C07D237/06 , C07D237/20 , C07D237/24 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D405/14 , C07D409/14 , C07D411/04 , C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D487/10 , C07D513/04 , Y02A50/465
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
-
2.发明申请公开(公告)号：US20160200717A1
公开(公告)日：2016-07-14
申请号：US14823605
申请日：2015-08-11
Applicant: Cytokinetics, Inc.
Inventor： Luke W. Ashcroft , Gustave Bergnes , Scott Collibee , Chihyuan Chuang , Jeff Gardina , Bradley P. Morgan , Alex R Muci , Xiangping Qian , Antonio Romero , Jeffrey Warrington , Zhe Yang
IPC: C07D417/14 , C07D213/75 , C07D401/14 , C07D253/07 , C07D403/04 , C07D213/74 , C07D401/12
CPC classification number: C07D213/74 , C07D213/75 , C07D213/78 , C07D213/82 , C07D215/38 , C07D215/48 , C07D253/07 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D417/04 , C07D417/14
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R2, R4, R5, R6, R7, R8, R9, X, Z1, Z2, Z3, Z4 and m are as defined herein.Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US10765624B2
公开(公告)日：2020-09-08
申请号：US16352626
申请日：2019-03-13
Applicant: Cytokinetics, Inc.
Inventor： Zhe Yang , Alex R. Muci , Jeffrey Warrington , Gustave Bergnes , Bradley P. Morgan , Chihyuan Chuang , Antonio Romero , Scott Collibee , Xiangping Qian , Pu-Ping Lu
IPC: A61K9/00 , C07D403/04 , C07D239/42 , C07D513/04 , C07D495/04 , C07D471/04 , C07D417/04 , C07D413/14 , C07D409/14 , C07D401/14 , C07D401/12 , C07D239/48 , C07D403/10 , C07D401/04 , C07D417/14
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
-
Patent Agency Ranking
公开(公告)号：US10272030B2
公开(公告)日：2019-04-30
申请号：US15645977
申请日：2017-07-10
Applicant: CYTOKINETICS, INC.
Inventor： Zhe Yang , Alex R. Muci , Jeffrey Warrington , Gustave Bergnes , Bradley P. Morgan , Chihyuan Chuang , Antonio Romero , Scott Collibee , Xiangping Qian , Pu-Ping Lu
IPC: A61K9/00 , C07D513/04 , C07D471/04 , C07D417/14 , C07D413/14 , C07D409/14 , C07D403/10 , C07D403/04 , C07D401/14 , C07D401/12 , C07D401/04 , C07D239/48 , C07D239/42 , C07D495/04
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US09730886B2
公开(公告)日：2017-08-15
申请号：US14594315
申请日：2015-01-12
Applicant: Cytokinetics, Inc.
Inventor： Zhe Yang , Alex R. Muci , Jeffrey Warrington , Gustave Bergnes , Bradley P. Morgan , Chihyuan Chuang , Antonio Romero , Scott Collibee , Xiangping Qian , Pu-Ping Lu
IPC: C07D403/04 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14 , C07D239/42 , C07D409/14 , C07D513/04 , C07D495/04 , A61K9/00 , C07D239/48 , C07D401/12 , C07D471/04 , C07D403/10
CPC classification number: A61K9/0014 , A61K9/0019 , A61K9/0034 , A61K9/0043 , A61K9/0048 , A61K9/0053 , A61K9/006 , A61K9/007 , C07D239/42 , C07D239/48 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D495/04 , C07D513/04
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
-
6.发明授权公开(公告)号：US09994528B2
公开(公告)日：2018-06-12
申请号：US14823605
申请日：2015-08-11
Applicant: Cytokinetics, Inc.
Inventor： Luke W. Ashcraft , Gustave Bergnes , Scott Collibee , Chihyuan Chuang , Jeff Gardina , Bradley P. Morgan , Alex R Muci , Xiangping Qian , Antonio Romero , Jeffrey Warrington , Zhe Yang
IPC: C07D213/74 , C07D213/75 , C07D401/12 , C07D401/14 , C07D417/14 , C07D417/04 , C07D403/04 , A61K31/44 , A61K31/4427 , A61P21/00 , A61P21/04 , C07D213/78 , C07D213/82 , C07D215/48 , C07D253/07 , C07D215/38 , C07D403/10
CPC classification number: C07D213/74 , C07D213/75 , C07D213/78 , C07D213/82 , C07D215/38 , C07D215/48 , C07D253/07 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D417/04 , C07D417/14
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R2, R4, R5, R6, R7, R8, R9, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11369565B2
公开(公告)日：2022-06-28
申请号：US16941079
申请日：2020-07-28
Applicant: Cytokinetics, Inc.
Inventor： Zhe Yang , Alex R. Muci , Jeffrey Warrington , Gustave Bergnes , Bradley P. Morgan , Chihyuan Chuang , Antonio Romero , Scott Collibee , Xiangping Qian , Pu-Ping Lu
IPC: A61K9/14 , A61K9/00 , C07D403/04 , C07D239/42 , C07D239/48 , C07D401/04 , C07D401/12 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D495/04 , C07D513/04 , C07D401/14 , C07D403/10
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.
Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US10076519B2
公开(公告)日：2018-09-18
申请号：US15463288
申请日：2017-03-20
Applicant: CYTOKINETICS, INC.
Inventor： Luke W. Ashcraft , Gustave Bergnes , Scott Collibee , Chihyuan Chuang , Jeff Gardina , Bradley P. Morgan , Alex R. Muci , Xiangping Qian , Jeffrey Warrington , Zhe Yang , Pu-Ping Lu , Antonio Romero
IPC: A61K31/501 , C07D403/02 , A61K31/50 , C07D237/06 , C07D231/56 , A61K31/16 , A61K31/166 , C07D213/16 , C07D207/26 , C07D211/76
CPC classification number: A61K31/50 , A61K31/16 , A61K31/166 , C07D207/26 , C07D211/76 , C07D213/16 , C07D231/56 , C07D237/06 , C07D237/20 , C07D237/24 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D405/14 , C07D409/14 , C07D411/04 , C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D487/10 , C07D513/04 , Y02A50/465
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.018 seconds)
